Review



ifx biosimilar sim0006 antibody  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bio X Cell ifx biosimilar sim0006 antibody
    Three donors (BC01, BC02, and BC03) were tested in triplicate (independent samples) to assess assay intra-day/intra-donor reproducibility, <t>infliximab</t> <t>(IFX)</t> concentration 10 μg/ml. (A) IFX heavy chain peptides (light orange); IFX light chain peptides (dark green). Complementarity-determining regions are shown in different colors according to the legend in the picture. (B) Venn plots for reproducibility assessment of technical replicates for peptide sequences. More details are in SI ( , , and ).
    Ifx Biosimilar Sim0006 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifx+biosimilar+sim0006+antibody/pmc10576005-164-4-7?v=Bio+X+Cell
    Average 90 stars, based on 1 article reviews
    ifx biosimilar sim0006 antibody - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics"

    Article Title: Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics

    Journal: Life Science Alliance

    doi: 10.26508/lsa.202302095

    Three donors (BC01, BC02, and BC03) were tested in triplicate (independent samples) to assess assay intra-day/intra-donor reproducibility, infliximab (IFX) concentration 10 μg/ml. (A) IFX heavy chain peptides (light orange); IFX light chain peptides (dark green). Complementarity-determining regions are shown in different colors according to the legend in the picture. (B) Venn plots for reproducibility assessment of technical replicates for peptide sequences. More details are in SI ( , , and ).
    Figure Legend Snippet: Three donors (BC01, BC02, and BC03) were tested in triplicate (independent samples) to assess assay intra-day/intra-donor reproducibility, infliximab (IFX) concentration 10 μg/ml. (A) IFX heavy chain peptides (light orange); IFX light chain peptides (dark green). Complementarity-determining regions are shown in different colors according to the legend in the picture. (B) Venn plots for reproducibility assessment of technical replicates for peptide sequences. More details are in SI ( , , and ).

    Techniques Used: Concentration Assay

    (A) Box plot of log 2 summed peptide abundances (named as protein abundance in the plot) comparison between FG-NHS (blue) and streptavidin beads (orange), on three different donors. (B) MHC-II-associated peptide proteomics heatmap showing the MHC-II eluted ligands from infliximab (IFX)-treated DCs. Only BC115 (responding to HC-IFX) peptides were shown, instead BC65 and BC125 did not show any IFX peptides. (C, D, E) Volcano plots of MHC-II ligand ratio abundance (streptavidin to FG-NHS ratio) for BC115, 65, and 125, respectively. Threshold: log 2 ratio = ±1.0, −log 10 P value = 1.3. For details about peptide quantification, please see .
    Figure Legend Snippet: (A) Box plot of log 2 summed peptide abundances (named as protein abundance in the plot) comparison between FG-NHS (blue) and streptavidin beads (orange), on three different donors. (B) MHC-II-associated peptide proteomics heatmap showing the MHC-II eluted ligands from infliximab (IFX)-treated DCs. Only BC115 (responding to HC-IFX) peptides were shown, instead BC65 and BC125 did not show any IFX peptides. (C, D, E) Volcano plots of MHC-II ligand ratio abundance (streptavidin to FG-NHS ratio) for BC115, 65, and 125, respectively. Threshold: log 2 ratio = ±1.0, −log 10 P value = 1.3. For details about peptide quantification, please see .

    Techniques Used: Quantitative Proteomics, Comparison

    MAPPs MHC-II peptides of five different HLA-genotyped donors. (A) MAPPs MHC-II peptides of infliximab HC and LC. (B, C) MAPPs MHC-II peptides of Bet v1a and KLH, respectively. (D) Donor clustering based on MHC-II ligandome (red: increased peptide expression; green: decreased peptide expression; black: same peptide expression; white: missing peptide, Euclidian distance was used for hierarchical clustering). Negative control (Ctrl neg) samples (untreated cells from the same donor) were also included in the MAPPs study.
    Figure Legend Snippet: MAPPs MHC-II peptides of five different HLA-genotyped donors. (A) MAPPs MHC-II peptides of infliximab HC and LC. (B, C) MAPPs MHC-II peptides of Bet v1a and KLH, respectively. (D) Donor clustering based on MHC-II ligandome (red: increased peptide expression; green: decreased peptide expression; black: same peptide expression; white: missing peptide, Euclidian distance was used for hierarchical clustering). Negative control (Ctrl neg) samples (untreated cells from the same donor) were also included in the MAPPs study.

    Techniques Used: Expressing, Negative Control

    (A) Box plot showing a normal distribution for the whole MHC-II-associated peptide proteomics MHC-II-eluted ligands. (B, C, D) Violin plots showing the distribution of the data for the different identified peptide lengths in the same five HLA-genotyped donors for (B) infliximab (yellow), (C) KLH (red), and (D) Bet v1a (blue). The median is represented by a white dot in the violin plot. The interquartile range (IQR) is the black bar in the center of violin. The lower/upper adjacent values (the black lines stretched from the bar that overlap with the two ends of Kernel density distribution) are defined as first quartile- 1.5 IQR and third quartile + 1.5 IQR respectively. Peptide lengths were arranged to an ascending order of median percentage frequency for each individual tested protein.
    Figure Legend Snippet: (A) Box plot showing a normal distribution for the whole MHC-II-associated peptide proteomics MHC-II-eluted ligands. (B, C, D) Violin plots showing the distribution of the data for the different identified peptide lengths in the same five HLA-genotyped donors for (B) infliximab (yellow), (C) KLH (red), and (D) Bet v1a (blue). The median is represented by a white dot in the violin plot. The interquartile range (IQR) is the black bar in the center of violin. The lower/upper adjacent values (the black lines stretched from the bar that overlap with the two ends of Kernel density distribution) are defined as first quartile- 1.5 IQR and third quartile + 1.5 IQR respectively. Peptide lengths were arranged to an ascending order of median percentage frequency for each individual tested protein.

    Techniques Used:



    Similar Products

    ifx biosimilar sim0006 antibody  (Bio X Cell)
    90
    Bio X Cell ifx biosimilar sim0006 antibody
    Three donors (BC01, BC02, and BC03) were tested in triplicate (independent samples) to assess assay intra-day/intra-donor reproducibility, <t>infliximab</t> <t>(IFX)</t> concentration 10 μg/ml. (A) IFX heavy chain peptides (light orange); IFX light chain peptides (dark green). Complementarity-determining regions are shown in different colors according to the legend in the picture. (B) Venn plots for reproducibility assessment of technical replicates for peptide sequences. More details are in SI ( , , and ).
    Ifx Biosimilar Sim0006 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ifx+biosimilar+sim0006+antibody/pmc10576005-164-4-7?v=Bio+X+Cell
    Average 90 stars, based on 1 article reviews
    ifx biosimilar sim0006 antibody - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Three donors (BC01, BC02, and BC03) were tested in triplicate (independent samples) to assess assay intra-day/intra-donor reproducibility, infliximab (IFX) concentration 10 μg/ml. (A) IFX heavy chain peptides (light orange); IFX light chain peptides (dark green). Complementarity-determining regions are shown in different colors according to the legend in the picture. (B) Venn plots for reproducibility assessment of technical replicates for peptide sequences. More details are in SI ( , , and ).

    Journal: Life Science Alliance

    Article Title: Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics

    doi: 10.26508/lsa.202302095

    Figure Lengend Snippet: Three donors (BC01, BC02, and BC03) were tested in triplicate (independent samples) to assess assay intra-day/intra-donor reproducibility, infliximab (IFX) concentration 10 μg/ml. (A) IFX heavy chain peptides (light orange); IFX light chain peptides (dark green). Complementarity-determining regions are shown in different colors according to the legend in the picture. (B) Venn plots for reproducibility assessment of technical replicates for peptide sequences. More details are in SI ( , , and ).

    Article Snippet: Model therapeutic antibodies were IFX biosimilar (SIM0006; BioXcell), Bs-mAb1 and Bs-mAb2 were internally produced at Merck KGaA, trastuzumab IgG1 was made at Merck KGaA.

    Techniques: Concentration Assay

    (A) Box plot of log 2 summed peptide abundances (named as protein abundance in the plot) comparison between FG-NHS (blue) and streptavidin beads (orange), on three different donors. (B) MHC-II-associated peptide proteomics heatmap showing the MHC-II eluted ligands from infliximab (IFX)-treated DCs. Only BC115 (responding to HC-IFX) peptides were shown, instead BC65 and BC125 did not show any IFX peptides. (C, D, E) Volcano plots of MHC-II ligand ratio abundance (streptavidin to FG-NHS ratio) for BC115, 65, and 125, respectively. Threshold: log 2 ratio = ±1.0, −log 10 P value = 1.3. For details about peptide quantification, please see .

    Journal: Life Science Alliance

    Article Title: Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics

    doi: 10.26508/lsa.202302095

    Figure Lengend Snippet: (A) Box plot of log 2 summed peptide abundances (named as protein abundance in the plot) comparison between FG-NHS (blue) and streptavidin beads (orange), on three different donors. (B) MHC-II-associated peptide proteomics heatmap showing the MHC-II eluted ligands from infliximab (IFX)-treated DCs. Only BC115 (responding to HC-IFX) peptides were shown, instead BC65 and BC125 did not show any IFX peptides. (C, D, E) Volcano plots of MHC-II ligand ratio abundance (streptavidin to FG-NHS ratio) for BC115, 65, and 125, respectively. Threshold: log 2 ratio = ±1.0, −log 10 P value = 1.3. For details about peptide quantification, please see .

    Article Snippet: Model therapeutic antibodies were IFX biosimilar (SIM0006; BioXcell), Bs-mAb1 and Bs-mAb2 were internally produced at Merck KGaA, trastuzumab IgG1 was made at Merck KGaA.

    Techniques: Quantitative Proteomics, Comparison

    MAPPs MHC-II peptides of five different HLA-genotyped donors. (A) MAPPs MHC-II peptides of infliximab HC and LC. (B, C) MAPPs MHC-II peptides of Bet v1a and KLH, respectively. (D) Donor clustering based on MHC-II ligandome (red: increased peptide expression; green: decreased peptide expression; black: same peptide expression; white: missing peptide, Euclidian distance was used for hierarchical clustering). Negative control (Ctrl neg) samples (untreated cells from the same donor) were also included in the MAPPs study.

    Journal: Life Science Alliance

    Article Title: Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics

    doi: 10.26508/lsa.202302095

    Figure Lengend Snippet: MAPPs MHC-II peptides of five different HLA-genotyped donors. (A) MAPPs MHC-II peptides of infliximab HC and LC. (B, C) MAPPs MHC-II peptides of Bet v1a and KLH, respectively. (D) Donor clustering based on MHC-II ligandome (red: increased peptide expression; green: decreased peptide expression; black: same peptide expression; white: missing peptide, Euclidian distance was used for hierarchical clustering). Negative control (Ctrl neg) samples (untreated cells from the same donor) were also included in the MAPPs study.

    Article Snippet: Model therapeutic antibodies were IFX biosimilar (SIM0006; BioXcell), Bs-mAb1 and Bs-mAb2 were internally produced at Merck KGaA, trastuzumab IgG1 was made at Merck KGaA.

    Techniques: Expressing, Negative Control

    (A) Box plot showing a normal distribution for the whole MHC-II-associated peptide proteomics MHC-II-eluted ligands. (B, C, D) Violin plots showing the distribution of the data for the different identified peptide lengths in the same five HLA-genotyped donors for (B) infliximab (yellow), (C) KLH (red), and (D) Bet v1a (blue). The median is represented by a white dot in the violin plot. The interquartile range (IQR) is the black bar in the center of violin. The lower/upper adjacent values (the black lines stretched from the bar that overlap with the two ends of Kernel density distribution) are defined as first quartile- 1.5 IQR and third quartile + 1.5 IQR respectively. Peptide lengths were arranged to an ascending order of median percentage frequency for each individual tested protein.

    Journal: Life Science Alliance

    Article Title: Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics

    doi: 10.26508/lsa.202302095

    Figure Lengend Snippet: (A) Box plot showing a normal distribution for the whole MHC-II-associated peptide proteomics MHC-II-eluted ligands. (B, C, D) Violin plots showing the distribution of the data for the different identified peptide lengths in the same five HLA-genotyped donors for (B) infliximab (yellow), (C) KLH (red), and (D) Bet v1a (blue). The median is represented by a white dot in the violin plot. The interquartile range (IQR) is the black bar in the center of violin. The lower/upper adjacent values (the black lines stretched from the bar that overlap with the two ends of Kernel density distribution) are defined as first quartile- 1.5 IQR and third quartile + 1.5 IQR respectively. Peptide lengths were arranged to an ascending order of median percentage frequency for each individual tested protein.

    Article Snippet: Model therapeutic antibodies were IFX biosimilar (SIM0006; BioXcell), Bs-mAb1 and Bs-mAb2 were internally produced at Merck KGaA, trastuzumab IgG1 was made at Merck KGaA.

    Techniques: